Roche has no immediate plans for a mega deal. CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships, a strategy it has had in place for some time, and which includes its July purchase of biotech Seragon for $1.7 billion.
Schwan says Roche evaluates potential moves based on how it would affect the balance between external opportunities and internal ones. “It can’t be that we have to put important internal opportunities on ice because of too-expensive acquisitions,” he says.
